Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow JonesNov 25 09:15 ET · Ratings

Anavex Life Sciences Price Target Maintained With a $46.00/Share by D. Boral Capital

Dow JonesNov 25 09:15 ET · Ratings

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

GlobeNewswireNov 25 07:30 ET

Express News | Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase Iib/III Data in a Reference Alzheimer’s Disease Journal

ReutersNov 25 07:30 ET

Calendar of U.S. Earnings Expected in the Week Ahead

Dow JonesNov 22 06:00 ET

Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More

Seeking AlphaNov 18 00:09 ET